Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

Proceedings of the National Academy of Sciences of the United States of America - 9 May 2006

Wendel Hans-Guido, de Stanchina Elisa, Cepero Enriqué, Ray Sagarika, Emig Michael, Fridman Jordan S, Veach Darren R, Bornmann William G, Clarkson Bayard, McCombie W Richard, Kogan Scott C, Hochhaus Andreas, Lowe Scott W

Abstract excerpt

Targeted cancer therapies exploit the continued dependence of cancer cells on oncogenic mutations. Such agents can have remarkable activity against some cancers, although antitumor responses are often heterogeneous, and resistance remains a clinical problem. To gain insight into factors that influence the action of a prototypical targeted drug, we studied the action of imatinib (STI-571, Gleevec) against murine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia

Share to Neoplasm Transplantation

Share to Piperazines

Share to Pyrimidines

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 16651519
DOI: 10.1073/pnas.0602402103
PMCID: PMC1455409

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.PMID 16651519Read ↗

A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment.Semantic proximity Read ↗

Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage.Semantic proximity Read ↗

p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice.Semantic proximity Read ↗

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)Semantic proximity Read ↗

Overriding imatinib resistance with a novel ABL kinase inhibitor.Semantic proximity Read ↗

p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.Semantic proximity Read ↗

The BCR-ABL Story: Bench to Bedside and BackSemantic proximity Read ↗

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.Semantic proximity Read ↗

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.Semantic proximity Read ↗

Acquired loss of p53 induces blastic transformation in p210bcr/abl-expressing hematopoietic cells: a transgenic study for blast crisis of human CMLSemantic proximity Read ↗

Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype.Semantic proximity Read ↗

BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.